Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole IV and oral suspension in infants with invasive fungal infection
2023-505613-24-00Phase 2Suspended
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of posaconazole in invasive mycoses, invasive candidiasis, invasive aspergillosis (IA) and 1 more (2 arms), sponsored by Merck & Co. Primary endpoints: Average concentration (Cavg) of single-dose IV posaconazole (Panel A), Maximum concentration (Cmax) of single-dose IV posaconazole (Panel A) and 12 more. Started Apr 2024; status: suspended.
02
Drugs
posaconazole
03
Conditions
invasive mycosesinvasive candidiasisinvasive aspergillosis (IA)Invasive Mold Infections (IMIs)
Beyond the preview
Go deeper on 2023-505613-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505613-24-00.